The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials.

Medicine (Baltimore) · 2015 · PMC4602912 · PMID 26313787

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Secondary Outcomes: PFS, ORR, DCR, and Serious Adverse Effects There was a favorable trend for the addition of EGFR-mAbs to the present standard chemotherapy in PFS, ORR, and DCR.

also in 993 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.